Literature DB >> 17532512

Strategies for developing protein tyrosine phosphatase inhibitors.

Lutz Tautz1, Tomas Mustelin.   

Abstract

Protein tyrosine phosphatases (PTPs) play vital roles in numerous cellular processes and are implicated in a growing number of human diseases, ranging from cancer to cardiovascular, immunological, infectious, neurological, and metabolic diseases. Here we present methods for developing small molecule inhibitors for these enzymes, starting with how to set up a high throughput chemical library screening for PTP inhibitors, how to confirm and prioritize hits, and how to circumnavigate possible pitfalls. Next, we present the relatively new hit generating method of in silico or virtual screening. We give an overview of existing software tools, describe how to choose and generate protein target structures and illustrate the procedure with examples. We then discuss how three-dimensional PTP structures can be analyzed in terms of their potential to bind small molecule inhibitors selectively over homologous proteins and how computer tools can be applied for lead optimization efforts. We finish with a perspective of how well these PTP inhibitors might perform as future drugs to treat human disease.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17532512     DOI: 10.1016/j.ymeth.2007.02.014

Source DB:  PubMed          Journal:  Methods        ISSN: 1046-2023            Impact factor:   3.608


  29 in total

1.  NMR-based design and evaluation of novel bidentate inhibitors of the protein tyrosine phosphatase YopH.

Authors:  Marilisa Leone; Elisa Barile; Jesus Vazquez; Angel Mei; Donald Guiney; Russel Dahl; Maurizio Pellecchia
Journal:  Chem Biol Drug Des       Date:  2010-04-28       Impact factor: 2.817

2.  Inhibition of hematopoietic protein tyrosine phosphatase augments and prolongs ERK1/2 and p38 activation.

Authors:  Eduard Sergienko; Jian Xu; Wallace H Liu; Russell Dahl; David A Critton; Ying Su; Brock T Brown; Xochella Chan; Li Yang; Ekaterina V Bobkova; Stefan Vasile; Hongbin Yuan; Justin Rascon; Sharon Colayco; Shyama Sidique; Nicholas D P Cosford; Thomas D Y Chung; Tomas Mustelin; Rebecca Page; Paul J Lombroso; Lutz Tautz
Journal:  ACS Chem Biol       Date:  2011-11-17       Impact factor: 5.100

Review 3.  Targeting protein tyrosine phosphatases for anticancer drug discovery.

Authors:  Latanya M Scott; Harshani R Lawrence; Saïd M Sebti; Nicholas J Lawrence; Jie Wu
Journal:  Curr Pharm Des       Date:  2010-06       Impact factor: 3.116

4.  Targeting Protein-Protein Interactions of Tyrosine Phosphatases with Microarrayed Fragment Libraries Displayed on Phosphopeptide Substrate Scaffolds.

Authors:  Megan Hogan; Medhanit Bahta; Kohei Tsuji; Trung X Nguyen; Scott Cherry; George T Lountos; Joseph E Tropea; Bryan M Zhao; Xue Zhi Zhao; David S Waugh; Terrence R Burke; Robert G Ulrich
Journal:  ACS Comb Sci       Date:  2019-01-31       Impact factor: 3.784

5.  In silico screening for PTPN22 inhibitors: active hits from an inactive phosphatase conformation.

Authors:  Shuangding Wu; Massimo Bottini; Robert C Rickert; Tomas Mustelin; Lutz Tautz
Journal:  ChemMedChem       Date:  2009-03       Impact factor: 3.466

Review 6.  Is Cdc25 a druggable target?

Authors:  John S Lazo; Peter Wipf
Journal:  Anticancer Agents Med Chem       Date:  2008-12       Impact factor: 2.505

7.  Multidentate small-molecule inhibitors of vaccinia H1-related (VHR) phosphatase decrease proliferation of cervix cancer cells.

Authors:  Shuangding Wu; Sofie Vossius; Souad Rahmouni; Ana V Miletic; Torkel Vang; Jesus Vazquez-Rodriguez; Fabio Cerignoli; Yutaka Arimura; Scott Williams; Tikva Hayes; Michel Moutschen; Stefan Vasile; Maurizio Pellecchia; Tomas Mustelin; Lutz Tautz
Journal:  J Med Chem       Date:  2009-11-12       Impact factor: 7.446

8.  Identifying potent, selective protein tyrosine phosphatase inhibitors from a library of Au(I) complexes.

Authors:  Mark R Karver; Divya Krishnamurthy; Rhushikesh A Kulkarni; Nunzio Bottini; Amy M Barrios
Journal:  J Med Chem       Date:  2009-11-12       Impact factor: 7.446

9.  Assessing Cellular Target Engagement by SHP2 (PTPN11) Phosphatase Inhibitors.

Authors:  Lester J Lambert; Celeste Romero; Douglas J Sheffler; Maria Celeridad; Nicholas D P Cosford; Lutz Tautz
Journal:  J Vis Exp       Date:  2020-07-17       Impact factor: 1.355

Review 10.  Toward a molecular understanding of the interaction of dual specificity phosphatases with substrates: insights from structure-based modeling and high throughput screening.

Authors:  Ahmet Bakan; John S Lazo; Peter Wipf; Kay M Brummond; Ivet Bahar
Journal:  Curr Med Chem       Date:  2008       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.